In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.52%, and the technology-centric Nasdaq increased by 0.7%.Prior to today's trading, shares of the company had lost 8.84% over the past month. This has lagged the Medical sector's gain of 0.52% and the S&P 500's loss of 5.56% in that time.Investors will be e ...

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $28.87, marking a +0.7% move from the previous day. This move lagged the S&P 500's daily gain of 1.59%. Meanwhile, the Dow experienced a rise of 1.39%, and the technology-dominated Nasdaq saw an increase of 1.63%.Coming into today, shares of the company had lost 14.9% in the past month. In that same time, the Medical sector lost 0.63%, while the S&P 500 lost 2.42%.Analysts and investors alike will be keeping a close eye on the perform ...

Financial Performance - The company has not generated any revenue to date and does not expect to until regulatory approval and commercialization of drug candidates [386]. - The company has incurred operating losses since inception and has not generated any revenues to date [410]. - In 2024, the net cash used in operating activities was $87.8 million, an increase of 19.5% from $73.4 million in 2023 [422][423]. - The net cash used in investing activities in 2024 was $553.4 million, significantly higher than $179.1 million in 2023, primarily due to investments of $1.1 billion [424]. - In 2024, net cash provided by financing activities was $612.5 million, a substantial increase from $271.4 million in 2023, mainly from common stock issuance [425][426]. - The company anticipates continued losses in the foreseeable future as it develops drug candidates and seeks regulatory approvals, necessitating additional capital [427]. - The company plans to finance future cash needs through public or private equity or debt offerings, but availability on acceptable terms is uncertain [427]. - As of December 31, 2024, cash and cash equivalents decreased to $26.7 million from $55.5 million in 2023, while short-term investments increased to $875.9 million from $306.6 million [432]. - The total cash and cash equivalents and short-term investments combined amounted to $902.6 million as of December 31, 2024, compared to $362.1 million in 2023 [432]. Research and Development - The company incurred $101.6 million in research and development expenses for the year ended December 31, 2024, compared to $63.8 million in 2023, reflecting a significant increase of approximately 59% [387]. - Research and development expenses increased to $101,644,000 in 2024 from $63,806,000 in 2023, representing a 59.3% increase [402]. - Research and development expenses were primarily driven by increased manufacturing costs, stock-based compensation, and salaries, despite a decrease in clinical study expenses [403]. - The Phase 2 VENTURE study of VK2735 demonstrated statistically significant mean body weight reductions of up to 14.7% from baseline after 13 weeks, with a 13.1% reduction compared to placebo [372]. - The Phase 1 clinical trial of VK2735's oral formulation showed dose-dependent mean body weight reductions of up to approximately 5.3% after 28 days [373]. - The VOYAGE study for VK2809 achieved its primary endpoint, with significant reductions in liver fat content from baseline to Week 12 compared to placebo [379]. - In the VOYAGE study, up to 75% of VK2809-treated patients achieved NASH/MASH resolution with no worsening of fibrosis, compared to 29% for placebo (p=0.0001) [380]. - The company plans to initiate Phase 3 clinical studies of VK2735 in the first half of 2025 based on FDA feedback [372]. - The company aims to pursue partnering or licensing opportunities for VK0214 prior to conducting additional clinical studies [383]. Administrative Expenses - General and administrative expenses are expected to continue increasing due to hiring, stock-based compensation, and compliance costs associated with being a public company [390]. - General and administrative expenses rose to $49,277,000 in 2024 from $37,021,000 in 2023, a 33.1% increase [404]. Financing Activities - The company completed an underwritten public offering in April 2023, raising gross proceeds of $287.5 million by selling 19,828,300 shares at $14.50 per share [415]. - In March 2024, the company completed another public offering, raising net proceeds of $597.1 million by selling 7,441,650 shares at $85.00 per share [418]. - A stock repurchase program was authorized in February 2025, allowing the company to buy back up to $250 million in shares over two years [419]. - The company has entered into an At-The-Market Equity Offering Sales Agreement with a potential offering price of up to $200 million under the 2023 Shelf Registration Statement [417]. Investment Portfolio - The investment portfolio is primarily composed of U.S. government securities, investment-grade corporate bonds, and money market funds, with no trading purposes [429][430]. - A hypothetical 100 basis point change in interest rates would affect interest income by approximately $0.9 million in 2024 and $0.3 million in 2023 [431]. - Other income, net increased significantly to $40,958,000 in 2024 from $14,932,000 in 2023, marking a 174.3% increase [407].

Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of V ...

Viking Therapeutics (NASDAQ: VKTX ) is down nearly 50% since it reported phase 1 data from a trial of oral VK2735 in obese/overweight patients in April 2024. I rated VKTX a buy at that time , as I believedScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or si ...

Shares of Viking Therapeutics (VKTX) rose nearly 8% on Friday after several third-party reports suggested that it was being eyed for a potential takeover by pharma giant Pfizer (PFE) . These reports even suggest that PFE has appointed Morgan Stanley as its advisor on the transaction.Viking is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subc ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.There's no secret to their success: Both companies have blockbuster weight-loss drugs. But the obesity market could soon have a new contender. Wall Street thinks this weight-loss drug stock could mor ...

Group 1: Hims & Hers Health Inc (HIMS) - HIMS shares increased by 17.5%, trading at $54.50, with a record peak of $56.71, marking a 438.7% year-over-year gain [2] - The company aired an advertisement during the Super Bowl and is preparing to release its fourth-quarter results on February 24 [2] - Historically, HIMS has experienced negative post-earnings reactions, with five out of the last eight sessions closing lower the day after earnings [2] Group 2: Novo Nordisk A/S (NVO) - NVO shares decreased by 3.1%, trading at $79.29, and have dropped 42.3% over the past nine months [3] - The company is nearing its 52-week low of $78.17, with five consecutive daily losses [3] - NVO has faced resistance at the $90 level since late December [3] Group 3: Viking Therapeutics Inc (VKTX) - VKTX shares fell by 2.1%, trading at $28.70, and are on track for their fifth loss in the last six sessions [4] - The stock recently hit its lowest level in 12 months, despite receiving an "outperform" rating from Scotiabank with a price target of $102 [4] - VKTX has a 58.3% deficit over the past nine months and has declined by 28.5% this year [4]

Nearly a year ago, Viking Therapeutics (VKTX 3.50%) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug.Viking Therapeutics' weight management candidate could produce blockbuster sales down the road, but this isn't enough to hold the attention of a stock market obsessed with artificial intelligence (AI). When the market closed on Feb. 5, shares of Viking Therapeutics were down about 65% from the peak they reached ...

Viking Therapeutics (VKTX) reported a fourth-quarter 2024 loss per share of 32 cents, wider than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 25 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it is yet to generate revenues.More on VKTX’s Q4 EarningsResearch and development expenses surged 51% year over year to $31 m ...